We are live on ! Find out more
CPHI icon

China Pharma Holdings

6 hedge funds and large institutions have $88.3K invested in China Pharma Holdings in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more capital invested

Capital invested by funds: $40.4K → $88.3K (+$47.8K)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

20% more funds holding

Funds holding: 56 (+1)

0.09% more ownership

Funds ownership: 0.09%0.18% (+0.09%)

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change

CPHI Hedge Fund Activity: Q1 2025 in Review

6 of the 7,466 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q1 2025, worth a combined $88.3K — up 118% from $40.4K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CPHI positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, adding an estimated $16.7K. The largest seller was Two Sigma Securities, cutting an estimated $10.2K.

  • 6 institutional investors held China Pharma Holdings (CPHI) as of Q1 2025, up from 5 in Q4 2024.
  • Funds reported $88.3K of China Pharma Holdings stock for Q1 2025, up 118% quarter-over-quarter.
  • 3 funds opened new China Pharma Holdings positions in Q1 2025 and 2 closed out, a net change of +1 holder.
  • The largest China Pharma Holdings buyer in Q1 2025 was UBS Group, an estimated $16.7K added.
  • The largest China Pharma Holdings seller in Q1 2025 was Two Sigma Securities, an estimated $10.2K sold.

Based on aggregated 13F filings for Q1 2025.